Clinical Trials in Chieti, Italy
17 recruiting
Showing 1–20 of 20 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled399 locationsNCT06531824
Recruiting
Phase 2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Chronic Kidney Disease
Boehringer Ingelheim416 enrolled153 locationsNCT06926660
Recruiting
Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Depressive Disorder, Major
Janssen Research & Development, LLC752 enrolled200 locationsNCT06559306
Recruiting
Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Chronic Kidney Disease
Novo Nordisk A/S465 enrolled147 locationsNCT06717698
Recruiting
Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled386 locationsNCT06141473
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
Dravet SyndromeTuberous Sclerosis ComplexLennox Gastaut Syndrome
Jazz Pharmaceuticals100 enrolled18 locationsNCT05485831
Recruiting
REal-life ON PARKinson's - ITaly (REONPARK-IT)
Parkinson Disease
Bial - Portela C S.A.200 enrolled20 locationsNCT07403799
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340
Recruiting
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
AnxietyAnhedoniaCognition+5 more
Riccardo Guglielmo100 enrolled4 locationsNCT07146503
Recruiting
Prevention ICONA Dedicated Ensemble
HIV-1-infectionHIVPrEP+3 more
Fondazione ICONA5,000 enrolled53 locationsNCT07186244
Recruiting
Phase 3
MYTHS - MYocarditis THerapy With Steroids
Myocarditis Acute
Niguarda Hospital288 enrolled49 locationsNCT05150704
Recruiting
Phase 1Phase 2
Peritoneal Ultrafiltration in Cardio Renal Syndrome.
Congestive Heart Failure
Iperboreal Pharma Srl84 enrolled3 locationsNCT03994874
Recruiting
Phase 3
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
End Stage Renal Disease
Iperboreal Pharma Srl170 enrolled41 locationsNCT03994471
Recruiting
Phase 3
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Mesotheliomas Pleural
Gruppo Oncologico Italiano di Ricerca Clinica162 enrolled19 locationsNCT04996017
Recruiting
BRING-UP 3 Heart Failure
Heart Failure
Heart Care Foundation10,000 enrolled187 locationsNCT06279988
Recruiting
Not Applicable
Translational Biomarkers in Accelerated Neuromodulation for Treatment-resistant Depression
Treatment Resistant Depression
ITAB - Institute for Advanced Biomedical Technologies80 enrolled1 locationNCT05798143